Morfine Hcl Teva (Morphine Hydrochloride)

Morphine hydrochloride works by binding to μ‑opioid receptors in the brain and spinal cord. This activation blocks the transmission of pain signals, reduces the perception of pain, and produces sedation and a sense of well‑being.

The dose is individualized and set by the prescribing clinician based on the severity of pain, patient age, weight, organ function, and prior opioid exposure. Dosage adjustments are made to achieve adequate pain relief while minimizing side effects.

Morphine Hydrochloride is classified as Pregnancy Category C, meaning risk cannot be ruled out. It crosses the placenta and enters breast milk, so it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Morphine is a benchmark opioid with well‑known potency and a broad therapeutic window. Compared with fentanyl, it has a longer duration of action but requires more frequent dosing. Compared with oxycodone, morphine is typically administered intravenously or intramuscularly, offering rapid onset for acute pain.

Store the product at controlled room temperature, below 25 °C, in its original packaging. Protect it from light, moisture, and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution is discolored.

Morfine Hcl Teva is supplied as a sterile solution for injection. It may be given intramuscularly, intravenously, or subcutaneously by a qualified healthcare professional, following aseptic technique and appropriate dosing calculations.

The most serious risks include respiratory depression, which can be life‑threatening, severe allergic reactions such as anaphylaxis, and the development of physical dependence or withdrawal syndrome with prolonged use. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to morphine or any component of the formulation, those with severe respiratory depression, uncontrolled asthma, or acute bronchospasm, and individuals taking MAO inhibitors should not receive this medication. Contra‑indications are confirmed by the prescriber.